These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1552 related items for PubMed ID: 18449410

  • 1. Heparin and low-molecular-weight heparin.
    Gray E, Mulloy B, Barrowcliffe TW.
    Thromb Haemost; 2008 May; 99(5):807-18. PubMed ID: 18449410
    [Abstract] [Full Text] [Related]

  • 2. Heparin and low molecular weight heparin in thrombosis and beyond.
    Mousa SA.
    Curr Opin Investig Drugs; 2002 Aug; 3(8):1181-6. PubMed ID: 12211411
    [Abstract] [Full Text] [Related]

  • 3. An algal sulfated galactan has an unusual dual effect on venous thrombosis due to activation of factor XII and inhibition of the coagulation proteases.
    Melo FR, Mourão PA.
    Thromb Haemost; 2008 Mar; 99(3):531-8. PubMed ID: 18327401
    [Abstract] [Full Text] [Related]

  • 4. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
    Fareed J, Iqbal O, Cunanan J, Demir M, Wahi R, Clarke M, Adiguzel C, Bick R.
    Int Angiol; 2008 Jun; 27(3):176-92. PubMed ID: 18506123
    [Abstract] [Full Text] [Related]

  • 5. Low-molecular-weight heparin in the treatment of deep venous thrombosis.
    Hauer KE.
    West J Med; 1998 Oct; 169(4):240-4. PubMed ID: 9795594
    [Abstract] [Full Text] [Related]

  • 6. Direct inhibitors of coagulation proteins - the end of the heparin and low-molecular-weight heparin era for anticoagulant therapy?
    Laux V, Perzborn E, Heitmeier S, von Degenfeld G, Dittrich-Wengenroth E, Buchmüller A, Gerdes C, Misselwitz F.
    Thromb Haemost; 2009 Nov; 102(5):892-9. PubMed ID: 19888525
    [Abstract] [Full Text] [Related]

  • 7. Are all low molecular weight heparins equivalent in the management of venous thromboembolism?
    Fareed J, Jeske W, Fareed D, Clark M, Wahi R, Adiguzel C, Hoppensteadt D.
    Clin Appl Thromb Hemost; 2008 Oct; 14(4):385-92. PubMed ID: 18815137
    [Abstract] [Full Text] [Related]

  • 8. Low-molecular-weight heparin in outpatient treatment of DVT.
    Yeager BF, Matheny SC.
    Am Fam Physician; 1999 Feb 15; 59(4):945-52. PubMed ID: 10068716
    [Abstract] [Full Text] [Related]

  • 9. [State of the art: low-molecular-weight heparin and beyond].
    Cimminiello C, Casali G, Vitali L.
    Minerva Cardioangiol; 2000 Dec 15; 48(12 Suppl 1):61-5. PubMed ID: 11253343
    [Abstract] [Full Text] [Related]

  • 10. Treatment of cancer-associated thrombosis: distinguishing among antithrombotic agents.
    Pruemer J.
    Semin Oncol; 2006 Apr 15; 33(2 Suppl 4):S26-39; quiz S41-2. PubMed ID: 16638458
    [Abstract] [Full Text] [Related]

  • 11. Monitoring low molecular weight heparins.
    Garon JE.
    Clin Leadersh Manag Rev; 2003 Apr 15; 17(1):47-50. PubMed ID: 12592880
    [Abstract] [Full Text] [Related]

  • 12. Heparin: from animal organ extract to designer drug.
    Middeldorp S.
    Thromb Res; 2008 Apr 15; 122(6):753-62. PubMed ID: 17996279
    [Abstract] [Full Text] [Related]

  • 13. Managing cancer-related venous thromboembolic disease: low-molecular-weight heparins and beyond.
    O'Connell CL, Liebman HA.
    Expert Rev Hematol; 2008 Dec 15; 1(2):175-82. PubMed ID: 21082922
    [Abstract] [Full Text] [Related]

  • 14. Dalteparin: pharmacological properties and clinical efficacy in the prophylaxis and treatment of thromboembolic diseases.
    Pineo GF, Hull RD.
    Eur J Med Res; 2004 Apr 30; 9(4):215-24. PubMed ID: 15210402
    [Abstract] [Full Text] [Related]

  • 15. From heparins to factor Xa inhibitors and beyond.
    Alban S.
    Eur J Clin Invest; 2005 Mar 30; 35 Suppl 1():12-20. PubMed ID: 15701143
    [Abstract] [Full Text] [Related]

  • 16. [Anticoagulant activity of low-molecular-weight heparins obtained using a hydrolase complex].
    Drozd NN, Tolstenkov AS, Bannikova GE, Miftakhova NT, Lapikova ES, Makarov VA, Varlamov VP.
    Eksp Klin Farmakol; 2007 Mar 30; 70(6):19-24. PubMed ID: 18318190
    [Abstract] [Full Text] [Related]

  • 17. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials.
    van Doormaal FF, Raskob GE, Davidson BL, Decousus H, Gallus A, Lensing AW, Piovella F, Prins MH, Büller HR.
    Thromb Haemost; 2009 Apr 30; 101(4):762-9. PubMed ID: 19350123
    [Abstract] [Full Text] [Related]

  • 18. Survival of heparins, oral anticoagulants, and aspirin after the year 2010.
    Fareed J, Hoppensteadt DA, Fareed D, Demir M, Wahi R, Clarke M, Adiguzel C, Bick R.
    Semin Thromb Hemost; 2008 Feb 30; 34(1):58-73. PubMed ID: 18393143
    [Abstract] [Full Text] [Related]

  • 19. A review of the practical advantages of low molecular weight heparin in the treatment of cancer-related venous thromboembolism.
    Rhodes S, Bond S.
    Eur J Oncol Nurs; 2008 Dec 30; 12(5):425-9. PubMed ID: 18842458
    [Abstract] [Full Text] [Related]

  • 20. [New medical anticoagulants].
    Choussat R, Montalescot G.
    Rev Mal Respir; 1999 Nov 30; 16(5 Pt 2):985-95. PubMed ID: 10907447
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 78.